Skip to content
AACR 2026 现场信号· @ · X·· 2026-04-23Score60
Body · original

Data from the phase 2 CANOPY trial showed promising activity and manageable safety with cabozantinib plus nivolumab in mCRPC. #AACR26 https://t.co/yS8ISSakid

Heat 0 · 0 likes · 0 replies · 0 reposts

Conference abstracts
3793matched by 药名 cabozantinib
Preventing nk cell activation in the damaged liver induced by cabozantinib/pd-1 blockade increases survival in hepatocellular carcinoma models

Satoru Morita, Tomofumi Ando, Hiroto Kikuchi, Atsuyo Morita, Tatsuya Kobayashi, Grace Birch, Ryota Tanaka, Aya Matsui, Zhiping Ruan, Peigen Huang, Alexei Hernandez, Erin M. Coyne, Sarah M. Shin, Robin Kate Kelley, Mark Yarchoan, Stefan Halvorsen, Slim Sassi, Mari Mino Kenudson, Shadmehr Demehri, Rizwan Romee, Won Jin Ho, Dan Duda

Read the abstract →

Source: AACR 2026 现场信号 · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org